How does Schedule I classification affect cannabis research in the US?

Schedule I classification (Controlled Substances Act) creates extraordinary barriers to cannabis research that do not exist for any other major drug class. Key restrictions: (1) DEA registration required for all researchers — a lengthy, expensive process. (2) Until 2021, only one federally licensed cannabis supplier existed (University of Mississippi/NIDA), and researchers reported the product was of poor quality and unrepresentative of commercial cannabis. (3) Institutional barriers: universities and hospitals with federal funding risk losing grants if they conduct cannabis research without full DEA compliance. (4) Banking restrictions: cannabis businesses cannot use federal banking, complicating research funding. (5) International collaboration: US researchers cannot legally import cannabis from other countries for research. (6) IRB and FDA approval required for human studies, with additional DEA Schedule I research protocol approval. The practical result: most cannabis research is conducted in Israel, Canada, the Netherlands, and the UK — countries without equivalent restrictions. The 2024 DEA proposal to reschedule cannabis to Schedule III would significantly reduce (but not eliminate) these barriers.